EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING
2024
Преузимање 🢃
Аутори
Pavić, AleksandarĐuriš, Jelena
Vukotić, Goran
Obradović, Mina
Plačkić, Nikola
Остала ауторства
Dimkić, IvicaKekić, Dušan
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Fungal infections, once considered a rare disease,
have become an everyday problem in modern
societies, posing major challenges to global
health. It is estimated that more than one billion
people are affected by fungal infections and 1.6
million people succumb to these diseases every
year. Of the 600 species of fungi capable of causing
infections in humans, species of the genus
Candida cause more than 85% of infections, especially
C. albicans, which has become a serious
threat to human health in immunocompromised
and immunosuppressed individuals. Unfortunately,
the current arsenal of clinical drugs relies
on only four classes of approved drugs (polyenes,
azoles, echinocandins and allylamines), which
are only partially effective, resulting in incomplete
eradication of the fungal infection. In
addition, the serious side effects, ranging from
systemic or organ-specific toxicity to poor bioavailability
and low activity, significantly hamper
the clinical use of antifunga...ls. These problems
call for new effective and safe antifungal agents,but also for appropriate preclinical models to accurately
study potential adverse effects on the
human population and test their efficacy against
fungal infections. In this sense, zebrafish (Danio
rerio) embryos have become one of the most
powerful preclinical animal models in infection
biology and drug discovery, offering the unique
opportunity to simultaneously monitor the safety
and efficacy of the applied molecule in real
time. With the aim of providing a preclinical platform
for the identification of new safe antifungal
drugs to effectively control C. albicans infection,
we comprehensively tested the toxicity of 13
clinical antifungal drugs in the zebrafish embryo
model. The 21 toxicity endpoints, including
survival, teratogenicity, cardiotoxicity and hepatotoxicity,
were evaluated and compared with
adverse effects described in rats and humans. Of
the clinical drugs, the efficacy of fluconazole and
voriconazole was evaluated in the zebrafish - C.
albicans model of systemic and wound biofilm
infection.
Кључне речи:
zebrafish model / antifungal drugs / Candida albicans / infection modellingИзвор:
XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health, 2024, 140-140Издавач:
- Serbian Society for Microbiology
Напомена:
- Book of abstract: From biotechnology to human and planetary health XIII congress of microbiologists of Serbia with international participation Mikromed regio 5, ums series 24: 4th – 6th april 2024, Mona Plaza hotel, Belgrade, Serbia
Колекције
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Pavić, Aleksandar AU - Đuriš, Jelena AU - Vukotić, Goran AU - Obradović, Mina AU - Plačkić, Nikola PY - 2024 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2379 AB - Fungal infections, once considered a rare disease, have become an everyday problem in modern societies, posing major challenges to global health. It is estimated that more than one billion people are affected by fungal infections and 1.6 million people succumb to these diseases every year. Of the 600 species of fungi capable of causing infections in humans, species of the genus Candida cause more than 85% of infections, especially C. albicans, which has become a serious threat to human health in immunocompromised and immunosuppressed individuals. Unfortunately, the current arsenal of clinical drugs relies on only four classes of approved drugs (polyenes, azoles, echinocandins and allylamines), which are only partially effective, resulting in incomplete eradication of the fungal infection. In addition, the serious side effects, ranging from systemic or organ-specific toxicity to poor bioavailability and low activity, significantly hamper the clinical use of antifungals. These problems call for new effective and safe antifungal agents,but also for appropriate preclinical models to accurately study potential adverse effects on the human population and test their efficacy against fungal infections. In this sense, zebrafish (Danio rerio) embryos have become one of the most powerful preclinical animal models in infection biology and drug discovery, offering the unique opportunity to simultaneously monitor the safety and efficacy of the applied molecule in real time. With the aim of providing a preclinical platform for the identification of new safe antifungal drugs to effectively control C. albicans infection, we comprehensively tested the toxicity of 13 clinical antifungal drugs in the zebrafish embryo model. The 21 toxicity endpoints, including survival, teratogenicity, cardiotoxicity and hepatotoxicity, were evaluated and compared with adverse effects described in rats and humans. Of the clinical drugs, the efficacy of fluconazole and voriconazole was evaluated in the zebrafish - C. albicans model of systemic and wound biofilm infection. PB - Serbian Society for Microbiology C3 - XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health T1 - EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING EP - 140 SP - 140 UR - https://hdl.handle.net/21.15107/rcub_imagine_2379 ER -
@conference{ author = "Pavić, Aleksandar and Đuriš, Jelena and Vukotić, Goran and Obradović, Mina and Plačkić, Nikola", year = "2024", abstract = "Fungal infections, once considered a rare disease, have become an everyday problem in modern societies, posing major challenges to global health. It is estimated that more than one billion people are affected by fungal infections and 1.6 million people succumb to these diseases every year. Of the 600 species of fungi capable of causing infections in humans, species of the genus Candida cause more than 85% of infections, especially C. albicans, which has become a serious threat to human health in immunocompromised and immunosuppressed individuals. Unfortunately, the current arsenal of clinical drugs relies on only four classes of approved drugs (polyenes, azoles, echinocandins and allylamines), which are only partially effective, resulting in incomplete eradication of the fungal infection. In addition, the serious side effects, ranging from systemic or organ-specific toxicity to poor bioavailability and low activity, significantly hamper the clinical use of antifungals. These problems call for new effective and safe antifungal agents,but also for appropriate preclinical models to accurately study potential adverse effects on the human population and test their efficacy against fungal infections. In this sense, zebrafish (Danio rerio) embryos have become one of the most powerful preclinical animal models in infection biology and drug discovery, offering the unique opportunity to simultaneously monitor the safety and efficacy of the applied molecule in real time. With the aim of providing a preclinical platform for the identification of new safe antifungal drugs to effectively control C. albicans infection, we comprehensively tested the toxicity of 13 clinical antifungal drugs in the zebrafish embryo model. The 21 toxicity endpoints, including survival, teratogenicity, cardiotoxicity and hepatotoxicity, were evaluated and compared with adverse effects described in rats and humans. Of the clinical drugs, the efficacy of fluconazole and voriconazole was evaluated in the zebrafish - C. albicans model of systemic and wound biofilm infection.", publisher = "Serbian Society for Microbiology", journal = "XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health", title = "EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING", pages = "140-140", url = "https://hdl.handle.net/21.15107/rcub_imagine_2379" }
Pavić, A., Đuriš, J., Vukotić, G., Obradović, M.,& Plačkić, N.. (2024). EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING. in XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health Serbian Society for Microbiology., 140-140. https://hdl.handle.net/21.15107/rcub_imagine_2379
Pavić A, Đuriš J, Vukotić G, Obradović M, Plačkić N. EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING. in XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health. 2024;:140-140. https://hdl.handle.net/21.15107/rcub_imagine_2379 .
Pavić, Aleksandar, Đuriš, Jelena, Vukotić, Goran, Obradović, Mina, Plačkić, Nikola, "EMPOWERING ANTIFUNGAL DRUGS DISCOVERY THROUGH THE ZEBRAFISH-INFECTIOUS DISEASES MODELLING" in XIII Congress of microbiologists of Serbia: From biotechnology to human and planetary health (2024):140-140, https://hdl.handle.net/21.15107/rcub_imagine_2379 .